5 Analysts Have This to Say About Corcept Therapeutics
Portfolio Pulse from Benzinga Insights
Corcept Therapeutics (NASDAQ:CORT) has received various analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 2 indifferent. The average price target is $31.2, indicating an upside from the current price of $26.98. This average has increased by 6.67% from the previous target of $29.25.
October 02, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics has received mixed analyst ratings, with an average price target indicating an upside. The target has increased by 6.67% from the previous one.
The mixed analyst ratings indicate uncertainty, but the average price target suggests a potential upside for the stock. The increase in the target price also indicates a positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100